ORIC Pharmaceuticals to Present Cutting-Edge Research
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC), an innovative clinical-stage oncology firm, is set to present groundbreaking research at an upcoming symposium focused on molecular targets and cancer therapies. This event will take place from October 23 to 25, drawing experts and enthusiasts from the oncology field worldwide.
About the Presentation
The presentation will highlight a poster detailing the promising effects of ORIC-114, a highly selective and brain-penetrant inhibitor of EGFR and HER2. The findings position ORIC-114 as a leading candidate in treating patients with non-small cell lung cancer, particularly those with atypical mutations including EGFR's exon 20 insertions.
Poster Presentation Summary
Poster Title: ORIC-114: A Leading Inhibitor for Challenging Mutations
Poster Number: PB050
Session Focus: Molecular Targeted Agents
Date & Time: October 23, 2024, from 9:00 to 11:00 a.m. CEST
Location: Exhibition Hall
Key Findings Highlighted in the Abstract
The research revealed that ORIC-114 is an irreversible inhibitor with significant potency against challenging mutations such as exon 20 insertions. Clinical trials have demonstrated positive systemic and intracranial responses in patients afflicted with EGFR and HER2 mutations. In comprehensive preclinical tests, ORIC-114 showcased exceptional capabilities, excelling in brain penetrance and effective specificity against various mutations compared to other therapies like firmonertinib and zipalertinib.
Impact on Patients
This research emphasizes ORIC-114's potential as a transformative therapy for patients suffering from non-small cell lung cancer, especially those with advanced stages that include brain metastases. It’s crucial for ongoing clinical trials which aim to validate the effectiveness of this promising drug.
About ORIC Pharmaceuticals
ORIC Pharmaceuticals, Inc. is dedicated to enhancing patients' lives by addressing the critical issue of resistance in cancer treatments. The company's pipeline includes several innovative candidates: ORIC-114 targets EGFR and HER2 mutations, ORIC-944 focuses on prostate cancer through its mechanism against the polycomb repressive complex 2, and ORIC-533 is an inhibitor of CD73, crucial in the adenosine pathway, particularly for multiple myeloma sufferers.
In addition to these candidates, ORIC Pharmaceuticals is committed to developing precision medicines that target various resistance mechanisms in cancer, demonstrating its holistic approach to oncology drug development.
Connecting with ORIC Pharmaceuticals
For those interested in learning more about ORIC Pharmaceuticals and its innovative research, further information is available through their official website and social media platforms. Engage with them to keep updated on breakthroughs and ongoing clinical trials.
Frequently Asked Questions
What is ORIC-114?
ORIC-114 is a selective brain-penetrant inhibitor that targets EGFR and HER2, primarily developed for patients with non-small cell lung cancer.
Where will the presentation take place?
The poster will be showcased at the EORTC-NCI-AACR Symposium held in Barcelona, from October 23 to 25, at the Exhibition Hall.
What are the benefits of ORIC-114?
ORIC-114 has demonstrated significant efficacy against various atypical EGFR mutations and is designed to penetrate the brain barrier effectively.
Who can benefit from ORIC-114?
Patients with non-small cell lung cancer, particularly those with exon 20 mutations or active CNS metastases, may find this treatment applicable.
How can I learn more about ORIC Pharmaceuticals?
For more information, you can visit ORIC Pharmaceuticals' website or follow them on their social media platforms.
